Why the study?
This report updates previous surveillance reports by describing global circulating vaccine-derived poliovirus outbreaks during January 2021-December 2022 following the introduction of novel oral poliovirus vaccine type 2.
Population
88 active cVDPV outbreaks affecting 46 countries worldwide
Design
Surveillance report
Authors
Loading...
nOPV2 rollout may reduce cVDPV2 reversion risk; leaves open long-term effectiveness and safety data.
While cVDPV2 outbreaks and paralytic cases declined globally following the introduction of nOPV2, cVDPV1 outbreaks increased due to pandemic-related disruptions in routine immunization.
Bigouette et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: